This topic contains a solution. Click here to go to the answer

Author Question: The most common source of financing for EMS funding is: a. fee-for-service. c. private pay. b. ... (Read 145 times)

joesmith1212

  • Hero Member
  • *****
  • Posts: 549
The most common source of financing for EMS funding is:
 
  a. fee-for-service. c. private pay.
  b. subsidy from local entities. d. service contracts.

Question 2

As a rule, the less a paramedic uses a particular skill or procedure:
 
  a. the more frequently he should review that skill or procedure.
  b. his retention of that skill or procedure remains the same.
  c. the less he needs to practice that skill or procedure.
  d. the more it is evidence that the skill or procedure may no longer be necessary.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

fromAlphatoOmega22

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

a

Answer to Question 2

a




joesmith1212

  • Member
  • Posts: 549
Reply 2 on: Jul 3, 2018
Gracias!


AISCAMPING

  • Member
  • Posts: 347
Reply 3 on: Yesterday
Thanks for the timely response, appreciate it

 

Did you know?

The longest a person has survived after a heart transplant is 24 years.

Did you know?

After 5 years of being diagnosed with rheumatoid arthritis, one every three patients will no longer be able to work.

Did you know?

According to the National Institute of Environmental Health Sciences, lung disease is the third leading killer in the United States, responsible for one in seven deaths. It is the leading cause of death among infants under the age of one year.

Did you know?

Before a vaccine is licensed in the USA, the Food and Drug Administration (FDA) reviews it for safety and effectiveness. The CDC then reviews all studies again, as well as the American Academy of Pediatrics and the American Academy of Family Physicians. Every lot of vaccine is tested before administration to the public, and the FDA regularly inspects vaccine manufacturers' facilities.

Did you know?

Despite claims by manufacturers, the supplement known as Ginkgo biloba was shown in a study of more than 3,000 participants to be ineffective in reducing development of dementia and Alzheimer’s disease in older people.

For a complete list of videos, visit our video library